Korro Bio (NASDAQ: KRRO) revenue
Korro Bio reported revenue of $6.4m for fiscal 2025, 181.5% more than in fiscal 2024 ($2.3m). Since fiscal 2019 its revenue has fallen by 77.9%, an average decline of 22.3% a year.
Korro Bio's best year of the last 7 was fiscal 2020. The biggest drop was in fiscal 2021, −62.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $6.4m | +181.5% | −$121.9m | −1,906.4% |
| 2024 | $2.3m | — | −$91.9m | −4,047.1% |
| 2023 | $0.0m | — | −$84.5m | — |
| 2022 | $0.0m | −100.0% | −$59.0m | — |
| 2021 | $14.1m | −62.0% | −$84.0m | −597.3% |
| 2020 | $37.0m | +27.8% | −$27.6m | −74.5% |
| 2019 | $28.9m | — | −$20.7m | −71.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Korro Bio revenue compared with its sector
By revenue for its latest fiscal year, Korro Bio ranks 379th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Korro Bio, 181.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 377th | Whitehawk Therapeutics | $7.1m | −72.5% |
| 378th | Immunome | $6.9m | −23.2% |
| 379th | Korro Bio | $6.4m | 181.5% |
| 380th | Abeona Therapeutics | $5.8m | 37.1% |
| 381st | Lucid Diagnostics | $4.7m | 8.3% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Korro Bio
- How much revenue did Korro Bio make in fiscal 2025?
- Korro Bio reported revenue of $6.4m for fiscal 2025, compared with $2.3m in fiscal 2024.
- How much has the revenue of Korro Bio fallen?
- Between fiscal 2019 and fiscal 2025 it went from $28.9m to $6.4m: 77.9% less, an average decline of 22.3% a year.
- What was the best year for revenue at Korro Bio?
- Of its last 7 fiscal years, fiscal 2020, with $37.0m.
- Where does Korro Bio rank in its sector by revenue?
- It ranks 379th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Korro Bio come from?
- From the annual report (Form 10-K) that Korro Bio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Korro Bio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Korro Bio: the Korro Bio page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.